Dogwood Therapeutics Files DEFA14A

Ticker: DWTX · Form: DEFA14A · Filed: Oct 9, 2025 · CIK: 1818844

Dogwood Therapeutics, INC. DEFA14A Filing Summary
FieldDetail
CompanyDogwood Therapeutics, INC. (DWTX)
Form TypeDEFA14A
Filed DateOct 9, 2025
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, corporate-governance, disclosure

TL;DR

Dogwood Therapeutics (formerly Virios) filed its DEFA14A on 10/9/25. Standard disclosure.

AI Summary

Dogwood Therapeutics, Inc. filed a DEFA14A on October 9, 2025, reporting its corporate actions. The company, formerly known as Virios Therapeutics, Inc., is incorporated in Delaware and headquartered in Alpharetta, Georgia. This filing is a routine disclosure related to its status as a public company.

Why It Matters

This filing provides important disclosures for investors regarding Dogwood Therapeutics, Inc.'s corporate governance and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine disclosure (DEFA14A) and does not contain new material information that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEFA14A filing?

A DEFA14A filing, also known as a Definitive Proxy Statement, is filed by companies to solicit proxies from shareholders for annual or special meetings, providing detailed information about matters to be voted upon.

When was Dogwood Therapeutics, Inc. formerly known as Virios Therapeutics, Inc.?

The company's name changed from Virios Therapeutics, Inc. on December 17, 2020.

What is the primary business of Dogwood Therapeutics, Inc.?

Dogwood Therapeutics, Inc. is in the Pharmaceutical Preparations industry, with the Standard Industrial Classification code 2834.

Where are Dogwood Therapeutics, Inc.'s principal executive offices located?

The principal executive offices of Dogwood Therapeutics, Inc. are located at 44 Milton Avenue, Alpharetta, GA 30009.

What is the fiscal year end for Dogwood Therapeutics, Inc.?

The fiscal year end for Dogwood Therapeutics, Inc. is December 31.

Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-10-09 16:20:12

Key Financial Figures

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On October 9, 2025, the Company posted a presentation to its website that may be used by the Company from time to time with investors, analysts, collaborators, vendors or other third parties. A copy of the presentation is furnished as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including the information in the presentation attached as Exhibit 99.1 to this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Presentation, dated October 9, 2025 (furnished herewith). 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOGWOOD THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Chief Financial Officer, Corporate Secretary and Treasurer October 9, 2025 3

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on Read The Filing